Immunovant (IMVT) Cash & Equivalents Growth (3y) (2021 - 2026)

Immunovant (IMVT) Cash & Equivalents Growth (3y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -15.41%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 8.23%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 47.78%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 14.34%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 10.62%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -27.97%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 37.45%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -3.85%
10 Immunovant 8.63 Bn 7.83 Bn - 34.21%

Historic Data

Download Data
DateValue
Jun 30, 2026 34.21%
Mar 31, 2026 33.81%
Dec 31, 2025 31.98%
Sep 30, 2025 8.75%
Jun 30, 2025 11.92%
Mar 31, 2025 13.08%
Dec 31, 2024 -10.75%
Sep 30, 2024 -5.42%
Jun 30, 2024 13.90%
Dec 31, 2023 17.86%
Sep 30, 2023 -15.31%
Jun 30, 2023 5.59%
Mar 31, 2023 55.28%
Sep 30, 2022 531.62%
Jun 30, 2022 506.82%
Dec 31, 2021 1,074.83%